Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Five cases of prostatic cancer developed after transurethral resection of prostate for benign hypertrophy are reported. Duration of transurethral resection of prostate (TUR-P) to diagnosis of prostatic cancer ranged from one year and seven months to seven years and two months, on average four years and seven months and frequency of prostatic cancer after TUR-P was estimated at 1.2%. Four of five patients complained of macroscopic hematuria. The cystourethrogram showed the mass protruded in the dilated prostatic urethra or bladder-neck in four patients (80%), a remarkable finding, and four cases were at stage D. Risk of development of prostatic cancer is not decreased even after prostatectomy and prostatic carcinoma diagnosed after TUR-P often advances in stage. Therefore, periodical examinations of the patients who had a prior prostatectomy are very important.
 ...
PMID:[Prostatic cancer after transurethral resection for benign prostatic hypertrophy]. 138 92

Morphometric analysis was performed on 22 radical prostatectomy specimens of clinical stage A1 and 22 specimens of stage A2 prostate cancers. Of 44 stage A cancers (86%), 38 arose in the transition zone of the prostate, while only 6 were peripheral zone tumors. The subclassification into stages A1 and A2 based on the percentage of cancer in the transurethral resection specimen was not able reliably to separate patients with high-volume stage A cancer from those with low-volume stage A cancer. The same was true when the patients were subclassified according to the criteria of the TNM system (TNM 1987). However, all cases (n = 6) with Gleason grade 4 elements in the TUR chips had relatively high-volume residual TUR cancer (greater than or equal to 1.7 cm3) in the radical specimen. Unsuspected cancers unrelated to the incidental prostate cancer were found in 73% of the specimens. The vast majority (87%) were peripheral zone cancers. Eight unsuspected cancers were larger than the Stage A cancer, but only 2 of the 8 were larger than 1 cm3. Our data suggest that the subclassification of stage A into stages A1 and A2 or the subclassification according to the TNM criteria (TNM 1987) does not reliably separate patients who are at risk of cancer progression. Further diagnostic procedures are necessary in these patients. Post-TUR serum PSA levels (Yang) provided valuable additional information in this series. Post-TUR PSA levels increased with increasing residual cancer volume in the prostate. Below a post-TUR PSA of 1 ng/ml, total residual cancer volume was less than 0.4 cm3 in 7 of 8 cases.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Incidental prostate cancer: volume, location and degree of differentiation of the tumor in the radical prostatectomy specimen and value of subclassification to stage A1 and A2]. 172 22

The limits of curability of prostate cancer still have not been exactly defined. Data derived of randomized, retrospective comparative studies of patients with positive lymph nodes suggest an advantage in overall survival and cancer mortality if such tumors are treated by means of radical prostatectomy with immediate adjuvant endocrine therapy. An analysis of such publications, however, shows that the more favourable results are based on the unequal distribution of important prognostic factors. Several publications agree that adjuvant endocrine treatment in N+ disease leads to a prolongation of time to progression which is clinically and statistically significant. Up to now, however, a significant prolongation of survival has not been shown with early endocrine treatment. Patients have a choice between an initial short period of time until progression occurs if endocrine treatment is delayed. During this time they will be sexually potent. On the other hand, for the price of loss of potency and libido an initial longer period of time free of progression can be expected. It is unclear at this moment whether it makes sense to carry out a radical prostatectomy for palliative reasons. To come to a proper decision it is necessary to compare the risk of the untreated primary tumour and the risk of the radical prostatectomy in this situation. This comparison is very difficult and depends on factors which are not ready for comparison at this moment. Local progression under endocrine treatment is relatively rare and can usually be controlled by conservative means (TUR, radiotherapy). At this moment there are insufficient arguments to carry out palliative radical prostatectomy as a routine in lymph node positive patients.
 ...
PMID:[Radical prostatectomy and adjuvant endocrine treatment of prostatic cancer with lymphatic metastasis?]. 172 23

The serum, urine and tissue concentrations of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT), 5-fluorouracil (5-FU) and uracil were estimated in 11 patients with prostate cancer (4 cases treated by total prostatectomy and 7 cases by transurethral resection (TUR-P) after oral administration of UFT. The concentration of FT, 5-FU and uracil in the tumor tissue (micrograms/g) were 5.920 +/- 5.902, 0.018 +/- 0.012 (T/S; 2.20) and 7.785 +/- 4.151 in 4 patients treated by total prostatectomy and 1.943 +/- 1.355, 0.024 +/- 0.010 (T/S; 1.46) and 4.616 +/- 2.848 in 7 patients treated by transurethral resection of prostate. The concentrations of FT, 5-FU and uracil in the tumor tissue did not increase as compared with those in normal tissue in 4 cases treated by total prostatectomy.
 ...
PMID:[Studies on 5-FU concentration in serum and prostate cancer tissue after oral administration of UFT]. 192 71

The expression of the proliferation-associated antigen Ki-67 was studied in human prostatic cancer. The antigen was analyzed with an immuno-histochemical technique in TUR specimens. A correlation was seen between Ki-67 positivity and differentiation grade. All TUR specimens (15/15) with poorly differentiated carcinomas expressed the antigen. Moderately differentiated carcinomas constituted an intermediate group and slightly less than half of the cancers (12/27) were positive for the antigen. Only one of the highly differentiated carcinomas (1/12) expressed the antigen. All TUR specimens from patients with benign prostatic hyperplasia (8/8) were negative. The effect on Ki-67 positivity was also investigated in a human prostatic cancer heterotransplanted to nude mice and subjected to ionizing irradiation with or without concomitant estramustine treatment. The antigen expression was compared with that seen in tumour tissues from untreated mice and from mice treated with estramustine alone. A pronounced effect was seen in the combination treatment group with an approximately 50% reduction of the Ki-67 positive cells. The results are discussed in relation to prognosis and follow-up after radiation therapy and the possible use of estramustine in combination with radiation therapy.
 ...
PMID:Expression of Ki-67--a proliferation-associated antigen--in prostatic cancer. 202 2

In this study, we have investigated the model DNA values and the expression of estramustine-binding protein (EMBP) in formalin-fixed and paraffin-embedded TUR specimens from 76 untreated patients with prostatic cancer. In addition, specimens from 13 patients were analyzed for tumour EMBP expression only. Ploidy was measured as diploid, tetraploid and non-tetraploid aneuploid or aneuploid in the near-diploid region. All patients had been referred during 1978-1981, and were subjected to TUR due to urinary obstruction. Survival data were obtained for all patients through March 1988. Statistical analyses were performed using a Cox's regression model with respect to survival and cause specific survival and correlated to the DNA pattern and the expression of EMBP. The existence of a near-diploid aneuploid cell population as well as poor differentiation grade were both statistically significantly correlated with poor survival. Near-diploid aneuploid cell lines were seen in 9/76 (12%) of the patients and were also seen in well differentiated cancers (4/17). The expression of EMBP was most abundant in the moderately differentiated cancers. However, all prostatic cancer specimens investigated were positive for the antigen. Patients with poorly differentiated carcinomas and high EMBP expression showed a tendency towards better prognosis than those with poorly differentiated carcinomas and low EMBP expression. The present patient material was, however, too small to show a statistically significant correlation between EMBP and survival.
 ...
PMID:Modal DNA values and estramustine-binding protein (EMBP) as prognostic markers in prostatic cancer. 202 8

To determine the effect on immunoparameters of cryosurgery in cases of stage B prostatic cancer and to determine whether such changes were specifically related to the cryosurgery technique, immunoparameters were measured and compared with cases of prostatic hyperplasia treated by transurethral resection (TUR-P). A decrease in immunoparameters was recognized in the cryosurgery group at 1-3 days postoperatively (increase in IAP, decrease in NK cell activity, decrease in lymphocyte blastogenesis reaction to PHA). The protein histograms, immunoglobulin and IAP changed similarly after the two above procedures. These changes were thought to be due to the invasive nature of the procedures. However, some difference was seen between the cryosurgery group and the TUR-P group in terms of rate of lymphocyte blastogenesis reaction to PHA and Con A, IgG, complement and NK cell activity which might indicate a specific effect of cryosurgery different from TUR-P.
 ...
PMID:[Changes in immunoparameters following cryosurgery in prostate cancer]. 235 4

TUR chips from 89 men were analysed prospectively for androgen and oestrogen nuclear and cytoplasmic receptors (ANR, ACR, ONR, OCR). Patients were selected on the basis of suspicion of neoplastic change on clinical feel of the prostate. A control group of benign cases was also collected prospectively. Histological examination showed that 46 patients had prostatic carcinoma and 43 had benign prostatic hyperplasia. No difference was found between the 2 groups in terms of prevalence of any of the receptors or in levels of receptor in those who were positive. The patients with neoplastic changes were followed up for a median of 53 months (range 47-64). No significant effect on duration of survival was noted with any of the receptor variables but there was a beneficial association between cytoplasmic oestrogen receptor positivity and progression-free interval. Patients with T category 3 or 4 had a significantly higher chance of being ANR positive than those of lower T category and this may reflect sampling error. There appears to be some evidence to suggest that cytosol oestrogen receptor positivity has a prognostic role in prostate cancer, in terms of time to progression on hormone therapy. Receptor status did not influence survival.
 ...
PMID:Androgen and oestrogen receptor status in benign and neoplastic prostate disease. Study of prevalence and influence on time to progression and survival in prostate cancer treated by hormone manipulation. 247 22

The value of endorectal sonography for the diagnosis of prostatic cancer was established after retrospective interpretation of sonographic findings in 213 patients, without prior knowledge of either the clinical or pathological data. Endorectal sonography was performed by the authors with a mechanical sectorial high frequency (7.5 MHz) probe. A pathology report (73 biopsies, 52 TUR, 7 suprapubic adenomectomy specimens) was available from 132 patients: 25 pathological examinations were interpreted as normal; 41 adenomas; 24 prostatitis or fibrosis, and 42 cancers (5 clinical stage T0, 22 T1, 2 T2 and 13 T3). Specificity for the diagnosis of cancer was 65 or 81%, respectively, according to the normality reference considered, i.e. either the group of patients having a normal pathological control (90 patients) or the same group plus another group of patients with a normal rectal examination (171 patients). The sensitivity for the diagnosis of cancer was only 48%. 43% of cancers were falsely interpreted as prostatitis or adenomas and 9% as normal (2 T0 and 2 T1). The large proportion of local stages without capsular involvement (29 of 42) is partly responsible for this lack of sensitivity. Rectal examination and sonography are complementary techniques. In the same study, rectal examination had a 48% specificity and a 92% sensitivity.
 ...
PMID:Comparison of the diagnostic value of sonography and rectal examination in cancer of the prostate. 328 34

The value of endorectal sonography for the diagnosis of prostatic cancer was established after retrospective interpretation of sonographic data issued from 213 patients without prior knowledge of either clinical or pathological data. Endorectal sonography was performed with a mechanical sectorial high frequency (7.5 MHz) probe realized by the authors. A pathology report (73 biopsies, 52 TUR, 7 suprapubic adenomectomy specimens) was available for 132 patients: 25 pathological examinations were interpreted as normal, 41 adenomas, 24 prostatitis or fibrosis and 42 cancers (5 clinical stage T0, 22 T1, 2 T2 and 13 T3). Specificity for the diagnosis of cancer was respectively 65% or 79% according to the normality reference considered, i.e. either the group of patients having a normal pathological control (90 patients) or the same group plus another group of patients with a normal rectal examination (171 patients). Sensitivity for the diagnosis of cancer was only 48%: 53% of cancers were falsely interpreted as prostatitis or adenomas and 9% as normal (2 T0 and 2 T1). The large proportion of local stages without capsular involvement (29/42) is partly responsible for this lack of sensitivity. Sonography can reveal the presence of abnormalities in the echostructure of the gland but does not allow tissue characterization. Rectal examination and sonography are complementary techniques. In the same study, rectal examination had a 48% specificity and a 92% sensitivity.
 ...
PMID:[Comparative diagnostic value of ultrasonics and rectal examination in prostatic cancer in a series of 213 patients]. 353 41


1 2 3 4 Next >>